Biological activity of EXf, a peptide analogue of exendin-4

European Journal of Pharmacology

Volumn 628, Issue 1-3, 2010, Pages 261-267

  Song, Guang ming ^a   Huan, Yi ^a   Sun, Su juan ^a   Chen, Yue teng ^a   Liu, Quan ^a   Shen, Zhu fang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

(Mice); Glucose tolerance; Incretin mimetic; Insulin; NIT 1 cells

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMATE SODIUM; INCRETIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DRUG DOSE COMPARISON; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN RELEASE; INSULIN RESISTANCE; MOUSE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH EMPTYING;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BLOOD GLUCOSE; CELL LINE; CYCLIC AMP; FASTING; FEMALE; INSULIN; INTESTINE, SMALL; MALE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; POSTPRANDIAL PERIOD; PREGNANCY; PROMOTER REGIONS, GENETIC; RATS; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; VENOMS;

EID: 73649147322     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.021     Document Type: Article

References (19)

1. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
2. Bruce D.G., Chisholm D.J., Storlien L.H., and Kraegen E.W. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37 (1988) 736-744
3. Brunzell J.D., Robertson R.P., Lerner R.L., Hazzard W.R., Ensinck J.W., Bierman E.L., and Porte Jr. D. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J. Clin. Endocrinol. Metab. 42 (1976) 222-229
4. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., and Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
5. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
6. Degn K.B., Brock B., Juhl C.B., Djurhuus C.B., Grubert J., Kim D., Han J., Taylor K., Fineman M., and Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53 (2004) 2397-2403
7. Del Prato S., and Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 17 (2001) 164-174
8. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., Ghatei M.A., and Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol., Endocrinol Metabol. Gastrointest. Physiol. 281 (2001) E155-161
9. Egan J.M., Clocquet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 87 (2002) 1282-1290
10. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267 (1992) 7402-7405
11. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., and Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268 (1993) 19650-19655
12. Holst J.J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 18 (2002) 430-441
13. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
14. Nauck M.A. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm. Metab. Res. 36 (2004) 852-858
15. Nielsen L.L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov. Today 10 (2005) 703-710
16. Skoglund G., Hussain M.A., and Holz G.G. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 49 (2000) 1156-1164
17. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
18. Thorens B., Porret A., Bühler L., Deng S.P., Morel P., and Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42 (1993) 1678-1682
19. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann. Clin. Biochem. 6 (1969) 24-25